AbbVie plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback